Call Now Open
2026 Oxford-Harrington Rare Disease Scholar Award
December 23, 2025
Rates of obesity and associated fatty liver disease have risen as the world increasingly adopts energy-dense diets and sedentary lifestyles. Cleveland research team has discovered a new enzyme that is required to make fat. Blocking the enzyme prevented weight gain and lowered cholesterol. A three-in-one drug is being...
Continue Reading
February 08, 2024
Dr. Paul Tesar of Case Western Reserve University and Dr. Donald F. Weaver of University Health Network selected for their work targeting novel pathways in Alzheimer’s Continue Reading
February 06, 2024
New Scholar Award Accelerates Novel Therapies for Rare Diseases Continue Reading
January 03, 2024
Co-founder and president of Harrington Discovery Institute at University Hospitals receives highest professional distinction awarded solely to inventors Continue Reading
November 30, 2023
Sol-Gel Technologies, a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, begun Phase 3 testing of SGT-610 for Gorlin syndrome with the first patient screened. Continue Reading
October 25, 2023
ABX1100 is a first-in-class molecule representing a new approach to reducing toxic levels of glycogen that build up in muscles of patients with Pompe Disease. Continue Reading
October 04, 2023
Monoclonal antibodies could provide a much-needed tool to protect vulnerable populations from severe COVID-19 Continue Reading
October 03, 2023
The Therapeutics Accelerator will identify, fund and advance innovative projects from academic partners in the U.K. and U.S. with the goal to deliver 40 new potentially life-changing therapies for rare diseases into clinical trials over 10 years. Continue Reading
September 23, 2023
Agreement enables the development of therapeutics, including AcuraStem's AS-202 Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase Continue Reading
September 14, 2023
New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC) Continue Reading
July 05, 2023
New Orleans, LA – LSU Health New Orleans today announced that has exercised its option to receive an exclusive license to certain early-stage technology designed to slow the progression of DNA repeat expansion disorders.In DNA repeat expansion disorders, a segment of repeated DNA expands within a gene to cause disease. The... Continue Reading